Conversely, epithelial-specific VDR overexpression restores Cldn5 levels and confers protection against inflammation-induced tumors, establishing Cldn5 as a downstream target of VDR and highlighting the VDR–Cldn5 axis as a potential therapeutic target in IBD [157]. The gene discussed is CLDN5; the disease is inflammatory bowel disease.